Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(1.99)
# 2,968
Out of 4,876 analysts
52
Total ratings
30.36%
Success rate
-1.46%
Average return
Main Sectors:
Stocks Rated by Brandon Folkes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EPRX Eupraxia Pharmaceuticals | Initiates: Buy | $12 | $4.62 | +159.74% | 2 | Jun 26, 2025 | |
| CNTB Connect Biopharma Holdings | Assumes: Buy | $7 | $0.97 | +621.28% | 1 | Jun 12, 2025 | |
| PYPD PolyPid | Maintains: Buy | $11 → $13 | $3.58 | +263.13% | 3 | Jun 9, 2025 | |
| HRTX Heron Therapeutics | Initiates: Buy | $6 | $2.16 | +177.78% | 2 | Jun 9, 2025 | |
| MIST Milestone Pharmaceuticals | Assumes: Buy | $5 | $1.94 | +157.73% | 2 | Jun 5, 2025 | |
| CRDL Cardiol Therapeutics | Initiates: Buy | $9 | $1.47 | +512.24% | 1 | Jun 2, 2025 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $21 | $5.66 | +271.02% | 2 | May 28, 2025 | |
| RMTI Rockwell Medical | Initiates: Buy | $5 | $0.81 | +518.05% | 1 | Nov 14, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Buy | $12 | $3.51 | +241.88% | 1 | Nov 14, 2024 | |
| OMER Omeros | Initiates: Buy | $9 | $3.32 | +171.08% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.47 | +1,602.85% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $16 | $6.83 | +134.26% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $13 | $14.96 | -13.10% | 1 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $3.77 | +112.20% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $0.52 | +1,834.24% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $455 | $5.30 | +8,484.91% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $59 | $28.36 | +108.04% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $180 | $107.59 | +67.30% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $0.66 | +3,257.24% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $7.00 | +28.57% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $28 → $32 | $28.83 | +11.00% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22,000 | $1.82 | +1,208,691.21% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $22 | $29.90 | -26.42% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $78 → $40 | $65.90 | -39.30% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $50 | $14.74 | +239.21% | 1 | Jul 12, 2018 |
Eupraxia Pharmaceuticals
Jun 26, 2025
Initiates: Buy
Price Target: $12
Current: $4.62
Upside: +159.74%
Connect Biopharma Holdings
Jun 12, 2025
Assumes: Buy
Price Target: $7
Current: $0.97
Upside: +621.28%
PolyPid
Jun 9, 2025
Maintains: Buy
Price Target: $11 → $13
Current: $3.58
Upside: +263.13%
Heron Therapeutics
Jun 9, 2025
Initiates: Buy
Price Target: $6
Current: $2.16
Upside: +177.78%
Milestone Pharmaceuticals
Jun 5, 2025
Assumes: Buy
Price Target: $5
Current: $1.94
Upside: +157.73%
Cardiol Therapeutics
Jun 2, 2025
Initiates: Buy
Price Target: $9
Current: $1.47
Upside: +512.24%
Trevi Therapeutics
May 28, 2025
Initiates: Buy
Price Target: $21
Current: $5.66
Upside: +271.02%
Rockwell Medical
Nov 14, 2024
Initiates: Buy
Price Target: $5
Current: $0.81
Upside: +518.05%
Achieve Life Sciences
Nov 14, 2024
Initiates: Buy
Price Target: $12
Current: $3.51
Upside: +241.88%
Omeros
Nov 14, 2024
Initiates: Buy
Price Target: $9
Current: $3.32
Upside: +171.08%
Nov 14, 2024
Initiates: Buy
Price Target: $8
Current: $0.47
Upside: +1,602.85%
Sep 13, 2024
Reiterates: Buy
Price Target: $16
Current: $6.83
Upside: +134.26%
Aug 26, 2024
Initiates: Buy
Price Target: $13
Current: $14.96
Upside: -13.10%
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $3.77
Upside: +112.20%
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $0.52
Upside: +1,834.24%
Jun 13, 2024
Initiates: Buy
Price Target: $455
Current: $5.30
Upside: +8,484.91%
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $28.36
Upside: +108.04%
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $107.59
Upside: +67.30%
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.66
Upside: +3,257.24%
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $7.00
Upside: +28.57%
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $28.83
Upside: +11.00%
Aug 31, 2021
Initiates: Overweight
Price Target: $22,000
Current: $1.82
Upside: +1,208,691.21%
Aug 6, 2021
Downgrades: Neutral
Price Target: $30 → $22
Current: $29.90
Upside: -26.42%
May 7, 2020
Downgrades: Neutral
Price Target: $78 → $40
Current: $65.90
Upside: -39.30%
Jul 12, 2018
Maintains: Overweight
Price Target: $42 → $50
Current: $14.74
Upside: +239.21%